Skip to main content
Caplight Logo









Cytocast

Cytocast

Private
BudapestAI, Data & Cloud Infrastructurehttps://cytocast.com/

Last Round

Seed

Aug 1, 2023

Total Funding Raised

$2.05M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Cytocast is a biotechnology company that provides a drug discovery platform using computer simulations technology.

Sector

AI, Data & Cloud Infrastructure

Verticals

Drug Discovery, Biotechnology, Medical AI, ML Platforms

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

in-silico simulationside effect predictiondigital twinAI drug discoverywhole-cell simulationpreclinical safetypredictive toxicologycomputational drug discoverydrug developmentmechanistic simulationTechBioadverse event forecastingdigital biologysystems biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cytocast Comparables

Compare Cytocast with similar companies based on industry and business-model similarity.

Cytocast comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VeriSIM Life
88%
DeepLife
86%
InSilicoTrials Technologies
83%

Cytocast Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 1, 2023
GrantSep 26, 2022
Pre SeedDec 1, 2021

Key People

Founding team and executive leadership

Erzsébet Fichó

Chief Operating Officer Product Manager Founder

Founding Team

Attila Csikász-Nagy

Chief Executive Officer

Executive Team

István Reguly

Chief Technology Officer

Executive Team

Bence Keömley-Huszár

Vice President of Engineering, Chief Technology Officer

Executive Team

Cytocast Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors increased 49% MoM.

  • Jul 20, 2026

    Open roles increased to 5, 5x the trailing average.

Cytocast Filings

Explore SEC and related filing metadata, where available.

Cytocast filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cytocast's valuation, stock price, and market status.

Is Cytocast a public or private company?

Cytocast is a private company.

What is the current stock price of Cytocast?

Cytocast is a private company with no public stock price. No recent secondary market data is available.

How much is Cytocast worth (valuation)?

Valuation information for Cytocast is not publicly available.

Can I buy Cytocast stock?

Cytocast shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cytocast's last funding round?

Cytocast's most recent funding round was Seed on August 1, 2023.

Who are the main investors in Cytocast?

Key investors in Cytocast include Bonitás Investment Fund Management, Creative Accelerator, FastVentures, National Research, Development and Innovation Office (NKFIH), Zoiros Ventures.

Will Cytocast IPO soon?

No public IPO plans have been announced for Cytocast.

How can I track Cytocast secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cytocast's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBudapest
Employee Range21
Year Founded2019
Last FundingAug 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?